Hitting the nail on the head: combining oncolytic adenovirus-mediated virotherapy and immunomodulation for the treatment of glioma

Glioblastoma is a highly aggressive malignant brain tumor with a poor prognosis and the median survival 14.6 months. Immunomodulatory proteins and oncolytic viruses represent two treatment approaches that have recently been developed for patients with glioblastoma that could extend patient survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Panek, Wojciech K., Kane, J. Robert, Young, Jacob S., Rashidi, Aida, Kim, Julius W., Kanojia, Deepak, Lesniak, Maciej S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687697/
https://www.ncbi.nlm.nih.gov/pubmed/29179527
http://dx.doi.org/10.18632/oncotarget.20810

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687697/
https://www.ncbi.nlm.nih.gov/pubmed/29179527
http://dx.doi.org/10.18632/oncotarget.20810

Ejemplares similares